{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:07:40Z","timestamp":1790698060343,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2009,4,7]],"date-time":"2009-04-07T00:00:00Z","timestamp":1239062400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s00259-009-1120-2","type":"journal-article","created":{"date-parts":[[2009,4,6]],"date-time":"2009-04-06T08:15:50Z","timestamp":1239005750000},"page":"1443-1452","source":"Crossref","is-referenced-by-count":49,"title":["In vitro characterization of 177Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study"],"prefix":"10.1007","volume":"36","author":[{"given":"Flavio","family":"Forrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melpomeni","family":"Fani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Lohri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"M\u00fcller-Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Moldenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut R.","family":"Maecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,7]]},"reference":[{"key":"1120_CR1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","volume":"63","author":"GL Plosker","year":"2003","unstructured":"Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003;63:803\u201343. doi: 10.2165\/00003495-200363080-00005 .","journal-title":"Drugs"},{"key":"1120_CR2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s002770050576","volume":"79","author":"TA Johnson","year":"2000","unstructured":"Johnson TA, Press OW. Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates: the Seattle experience. Ann Hematol 2000;79:175\u201382. doi: 10.1007\/s002770050576 .","journal-title":"Ann Hematol"},{"key":"1120_CR3","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","volume":"96","author":"M Kaminski","year":"2000","unstructured":"Kaminski M, Estes J, Zasadny K, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000;96:1259\u201366.","journal-title":"Blood"},{"key":"1120_CR4","first-page":"637a","volume":"88","author":"D Maloney","year":"1996","unstructured":"Maloney D, Smith B, Appelbaum F. The antitumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines (abstract). Blood 1996;88:637a.","journal-title":"Blood"},{"key":"1120_CR5","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565\u201373. doi: 10.1200\/JCO.2004.00.9217 .","journal-title":"J Clin Oncol"},{"key":"1120_CR6","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","volume":"21","author":"TE Witzig","year":"2003","unstructured":"Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 2003;21:1263\u201370. doi: 10.1200\/JCO.2003.08.043 .","journal-title":"J Clin Oncol"},{"key":"1120_CR7","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","volume":"24","author":"OW Press","year":"2006","unstructured":"Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143\u20139. doi: 10.1200\/JCO.2006.05.8198 .","journal-title":"J Clin Oncol"},{"key":"1120_CR8","first-page":"64","volume":"27","author":"JL Murray","year":"2000","unstructured":"Murray JL. Monoclonal antibody treatment of solid tumors: a coming of age. Semin Oncol 2000;27:64\u201370; discussion 92\u2013100.","journal-title":"Semin Oncol"},{"key":"1120_CR9","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","volume":"14","author":"MS Kaminski","year":"1996","unstructured":"Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974\u201381.","journal-title":"J Clin Oncol"},{"key":"1120_CR10","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2001.19.19.3908","volume":"19","author":"BD Cheson","year":"2001","unstructured":"Cheson BD. Some like it hot! J Clin Oncol 2001;19:3908\u201311.","journal-title":"J Clin Oncol"},{"key":"1120_CR11","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441\u20139. doi: 10.1056\/NEJMoa041511 .","journal-title":"N Engl J Med"},{"key":"1120_CR12","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s002590000276","volume":"27","author":"GA Wiseman","year":"2000","unstructured":"Wiseman GA, White CA, Stabin M, Dunn WL, Erwin WD, Dahlbom M, et al. Phase I\/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000;27:766\u201377. doi: 10.1007\/s002590000276 .","journal-title":"Eur J Nucl Med"},{"key":"1120_CR13","first-page":"3281s","volume":"5","author":"GA Wiseman","year":"1999","unstructured":"Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitschek A, et al. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 1999;5:3281s\u20133286s.","journal-title":"Clin Cancer Res"},{"key":"1120_CR14","first-page":"672","volume":"30","author":"M Roselli","year":"1989","unstructured":"Roselli M, Schlom J, Gansow OA, Raubitschek A, Mirzadeh S, Brechbiel MW, et al. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1989;30:672\u201382.","journal-title":"J Nucl Med"},{"key":"1120_CR15","first-page":"84","volume":"31","author":"RL Wahl","year":"1990","unstructured":"Wahl RL, Wissing J, del Rosario R, Zasadny KR. Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation. J Nucl Med 1990;31:84\u20139.","journal-title":"J Nucl Med"},{"key":"1120_CR16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","volume":"72","author":"T Lindmo","year":"1984","unstructured":"Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77\u201389. doi: 10.1016\/0022-1759(84)90435-6 .","journal-title":"J Immunol Methods"},{"key":"1120_CR17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2174\/1389201013378572","volume":"2","author":"MG Stabin","year":"2001","unstructured":"Stabin MG, Brill AB. Monoclonal antibodies in the treatment of hematologic malignancies: radiation dosimetry aspects. Curr Pharm Biotechnol 2001;2:351\u20136. doi: 10.2174\/1389201013378572 .","journal-title":"Curr Pharm Biotechnol"},{"key":"1120_CR18","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1007\/s00259-002-0820-7","volume":"29","author":"K Scheidhauer","year":"2002","unstructured":"Scheidhauer K, Wolf I, Baumgartl HJ, Von Schilling C, Schmidt B, Reidel G, et al. Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002;29:1276\u201382. doi: 10.1007\/s00259-002-0820-7 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1120_CR19","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/028418601750444141","volume":"40","author":"P Bernhardt","year":"2001","unstructured":"Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol 2001;40:602\u20138. doi: 10.1080\/028418601750444141 .","journal-title":"Acta Oncol"},{"key":"1120_CR20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0360-3016(01)01663-7","volume":"51","author":"P Bernhardt","year":"2001","unstructured":"Bernhardt P, Benjegard SA, Kolby L, Johanson V, Nilsson O, Ahlman H, et al. Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Int J Radiat Oncol Biol Phys 2001;51:514\u201324. doi: 10.1016\/S0360-3016(01)01663-7 .","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1120_CR21","first-page":"150","volume":"48","author":"H Song","year":"2007","unstructured":"Song H, Du Y, Sgouros G, Prideaux A, Frey E, Wahl RL. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. J Nucl Med 2007;48:150\u20137.","journal-title":"J Nucl Med"},{"key":"1120_CR22","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cncr.10305","volume":"94","author":"GA Wiseman","year":"2002","unstructured":"Wiseman GA, Leigh B, Erwin WD, Lamonica D, Kornmehl E, Spies SM, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 2002;94:1349\u201357. doi: 10.1002\/cncr.10305 .","journal-title":"Cancer"},{"key":"1120_CR23","first-page":"465","volume":"44","author":"GA Wiseman","year":"2003","unstructured":"Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003;44:465\u201374.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-009-1120-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-009-1120-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-009-1120-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T09:30:29Z","timestamp":1589707829000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-009-1120-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,7]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1007\/s00259-009-1120-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,7]]}}}